Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Diagnostic and therapeutic colonoscopy and EGD; identifies every active endoscopist. Main billing specialty: gastroenterology.
Medicare fee-for-service colonoscopy & upper endoscopy cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 1% on average (255 state-years, 2020–2024): a close guide.
Professional codes (what the surgeon bills): CPT 45378, 45380, 45385, 45390, 43239, 43235, 43251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 88 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 34 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Fujifilm | 20 |
| Pentax Of America | 7 |
| Motus Gi Medical Technologies | 6 |
| Olympus | 6 |
| Lumendi | 5 |
| Ambu | 4 |
| Evoendo | 4 |
| Actuated Medical | 3 |
| Smart Medical Systems | 3 |
| Bpendo | 2 |
| Gi View | 2 |
| Medrobotics | 2 |
The 10 busiest do 3% of the cases CMS names in California; 676 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| ERCP & endoscopic ultrasound | 1,734 | 112,761−1.2%/yr | −1.2%/yr | 137,600 in 2030+3.4%/yr |
| Bronchoscopy & lung nodule | 1,570 | 101,765+4.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 1,451 | 361,322+0.6%/yr | +0.6%/yr | 112.01.0× | 55% | 413,200 in 2030+2.3%/yr |
| Florida | 1,186 | 280,238−2.5%/yr | −2.5%/yr | 131.01.1× | 59% | 307,900 in 2030+1.6%/yr |
| Texas | 1,233 | 247,310−2.7%/yr | −2.7%/yr | 119.71.0× | 52% | 265,400 in 2030+1.2%/yr |
| New York | 1,378 | 235,327−1.7%/yr | −1.7%/yr | 134.51.2× | 54% | 246,900 in 2030+0.8%/yr |
| Pennsylvania | 915 | 164,346−1.8%/yr | −1.8%/yr | 125.51.1× | 44% | 166,800 in 2030+0.2%/yr |
| Illinois | 754 | 159,886−2.7%/yr | −2.7%/yr | 119.61.0× | 31% | 174,100 in 2030+1.4%/yr |
| Ohio | 759 | 134,256−3.1%/yr | −3.1%/yr | 126.71.1× | 38% | 138,100 in 2030+0.5%/yr |
| New Jersey | 581 | 123,352−1%/yr | −1%/yr | 121.51.1× | 59% | 138,300 in 2030+1.9%/yr |
| Massachusetts | 512 | 113,822−0.9%/yr | −0.9%/yr | 123.61.1× | 22% | 128,100 in 2030+2%/yr |
| North Carolina | 544 | 112,191−5.4%/yr | −5.4%/yr | 117.81.0× | 61% | 111,000 in 2030−0.2%/yr |
| Virginia | 455 | 110,688−2.7%/yr | −2.7%/yr | 108.80.9× | 34% | 119,700 in 2030+1.3%/yr |
| Georgia | 495 | 93,642−4.3%/yr | −4.3%/yr | 113.01.0× | 53% | 102,100 in 2030+1.5%/yr |
| Maryland | 357 | 91,101−2.7%/yr | −2.7%/yr | 105.10.9× | 65% | 97,500 in 2030+1.1%/yr |
| Michigan | 560 | 87,395−7.5%/yr | −7.5%/yr | 108.40.9× | 36% | 82,100 in 2030−1%/yr |
| South Carolina | 284 | 79,795−2.9%/yr | −2.9%/yr | 120.41.0× | 49% | 89,900 in 2030+2%/yr |
| Indiana | 415 | 79,616−4.3%/yr | −4.3%/yr | 117.31.0× | 30% | 80,600 in 2030+0.2%/yr |
| Tennessee | 338 | 78,991−4.4%/yr | −4.4%/yr | 117.01.0× | 47% | 84,100 in 2030+1%/yr |
| Washington | 393 | 77,215−3.7%/yr | −3.7%/yr | 104.50.9× | 45% | 78,700 in 2030+0.3%/yr |
| Arizona | 351 | 76,510−1%/yr | −1%/yr | 107.40.9× | 56% | 84,500 in 2030+1.7%/yr |
| Missouri | 371 | 72,989−5%/yr | −5%/yr | 122.51.1× | 27% | 74,000 in 2030+0.2%/yr |
| Wisconsin | 332 | 60,336−2.2%/yr | −2.2%/yr | 111.61.0× | 20% | 63,900 in 2030+1%/yr |
| Kentucky | 300 | 54,179−6.2%/yr | −6.2%/yr | 123.01.1× | 25% | 51,300 in 2030−0.9%/yr |
| Colorado | 277 | 51,857−1.4%/yr | −1.4%/yr | 110.71.0× | 57% | 56,700 in 2030+1.5%/yr |
| Louisiana | 259 | 49,097−5.9%/yr | −5.9%/yr | 125.41.1× | 50% | 47,000 in 2030−0.7%/yr |
| Minnesota | 399 | 47,636−3.7%/yr | −3.7%/yr | 109.91.0× | 35% | 59,400 in 2030+3.8%/yr |
| Alabama | 240 | 44,415−7.6%/yr | −7.6%/yr | 105.80.9× | 42% | 41,100 in 2030−1.3%/yr |
| Oklahoma | 189 | 42,798−5.6%/yr | −5.6%/yr | 91.00.8× | 28% | 41,600 in 2030−0.5%/yr |
| Mississippi | 126 | 39,544−7.4%/yr | −7.4%/yr | 108.90.9× | 60% | 37,000 in 2030−1.1%/yr |
| Connecticut | 245 | 39,442−4.5%/yr | −4.5%/yr | 124.11.1× | 50% | 44,000 in 2030+1.8%/yr |
| Kansas | 167 | 36,685−2%/yr | −2%/yr | 93.10.8× | 28% | 39,000 in 2030+1%/yr |
| Oregon | 259 | 35,214−3%/yr | −3%/yr | 87.60.8× | 43% | 37,100 in 2030+0.9%/yr |
| Arkansas | 152 | 33,269−5.9%/yr | −5.9%/yr | 91.10.8× | 50% | 32,200 in 2030−0.5%/yr |
| Iowa | 161 | 33,135−2.3%/yr | −2.3%/yr | 76.70.7× | 39% | 35,000 in 2030+0.9%/yr |
| Nebraska | 135 | 27,462−1.7%/yr | −1.7%/yr | 108.20.9× | 51% | 28,600 in 2030+0.7%/yr |
| Nevada | 98 | 24,594−2.4%/yr | −2.4%/yr | 89.00.8× | 70% | 25,500 in 2030+0.6%/yr |
| Utah | 118 | 24,136−2.4%/yr | −2.4%/yr | 114.81.0× | 32% | 23,500 in 2030−0.5%/yr |
| New Hampshire | 83 | 23,743−2%/yr | −2%/yr | 107.60.9× | 28% | 31,200 in 2030+4.7%/yr |
| Idaho | 83 | 19,523−0.2%/yr | −0.2%/yr | 99.40.9× | 37% | 27,700 in 2030+6%/yr |
| Delaware | 61 | 18,560−2.7%/yr | −2.7%/yr | 110.81.0× | 57% | 21,200 in 2030+2.2%/yr |
| New Mexico | 87 | 16,821−4.2%/yr | −4.2%/yr | 75.90.7× | 40% | 17,500 in 2030+0.7%/yr |
| West Virginia | 90 | 15,764−9.7%/yr | −9.7%/yr | 78.60.7× | 4% | 14,300 in 2030−1.6%/yr |
| South Dakota | 70 | 15,668−1.4%/yr | −1.4%/yr | 124.21.1× | 20% | 16,700 in 2030+1%/yr |
| Montana | 43 | 13,022−1.4%/yr | −1.4%/yr | 69.90.6× | 21% | 14,500 in 2030+1.8%/yr |
| Maine | 77 | 12,348−6.2%/yr | −6.2%/yr | 81.70.7× | 16% | 12,100 in 2030−0.4%/yr |
| Rhode Island | 62 | 12,155−5.7%/yr | −5.7%/yr | 139.81.2× | 57% | 12,900 in 2030+1%/yr |
| Alaska | 57 | 10,213+5.1%/yr | +5.1%/yr | 85.00.7× | 43% | 11,900 in 2030+2.5%/yr |
| North Dakota | 47 | 10,191−0.7%/yr | −0.7%/yr | 105.10.9× | 16% | 11,000 in 2030+1.3%/yr |
| Hawaii | 53 | 9,802−0.3%/yr | −0.3%/yr | 80.00.7× | 46% | 11,300 in 2030+2.4%/yr |
| Wyoming | 33 | 7,481−3.1%/yr | −3.1%/yr | 69.70.6× | 54% | 8,320 in 2030+1.8%/yr |
| Vermont | 43 | 7,313−0.6%/yr | −0.6%/yr | 65.80.6× | 14% | 14,500 in 2030+12%/yr |
| District of Columbia | 54 | 6,341−4.7%/yr | −4.7%/yr | 103.70.9× | 56% | 6,640 in 2030+0.8%/yr |
Product codes: FDF (colonoscope and accessories, flexible/rigid), FDS (gastroscope and accessories, flexible/rigid). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +2 pts since 2019, to 46%.
| 172,300 in 2030+9.2%/yr |
In 2025, 27 companies reported engagement with surgeons in the covered states worth $6.5M in consulting, speaking, meals and travel tied to these products, about $365 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.